Merck
CN
  • TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.

TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.

Epigenetics (2014-12-04)
Horacio Cardenas, Edyta Vieth, Jiyoon Lee, Mathew Segar, Yunlong Liu, Kenneth P Nephew, Daniela Matei
摘要

A key step in the process of metastasis is the epithelial-to-mesenchymal transition (EMT). We hypothesized that epigenetic mechanisms play a key role in EMT and to test this hypothesis we analyzed global and gene-specific changes in DNA methylation during TGF-β-induced EMT in ovarian cancer cells. Epigenetic profiling using the Infinium HumanMethylation450 BeadChip (HM450) revealed extensive (P < 0.01) methylation changes after TGF-β stimulation (468 and 390 CpG sites altered at 48 and 120 h post cytokine treatment, respectively). The majority of gene-specific TGF-β-induced methylation changes occurred in CpG islands located in or near promoters (193 and 494 genes hypermethylated at 48 and 120 h after TGF-β stimulation, respectively). Furthermore, methylation changes were sustained for the duration of TGF-β treatment and reversible after the cytokine removal. Pathway analysis of the hypermethylated loci identified functional networks strongly associated with EMT and cancer progression, including cellular movement, cell cycle, organ morphology, cellular development, and cell death and survival. Altered methylation and corresponding expression of specific genes during TGF-β-induced EMT included CDH1 (E-cadherin) and COL1A1 (collagen 1A1). Furthermore, TGF-β induced both expression and activity of DNA methyltransferases (DNMT) -1, -3A, and -3B, and treatment with the DNMT inhibitor SGI-110 prevented TGF-β-induced EMT. These results demonstrate that dynamic changes in the DNA methylome are implicated in TGF-β-induced EMT and metastasis. We suggest that targeting DNMTs may inhibit this process by reversing the EMT genes silenced by DNA methylation in cancer.

材料
货号
品牌
产品描述

Sigma-Aldrich
氢氧化钠, ACS reagent, ≥97.0%, pellets
Sigma-Aldrich
氢氧化钠, reagent grade, ≥98%, pellets (anhydrous)
Sigma-Aldrich
氢氧化钠 溶液, 50% in H2O
Sigma-Aldrich
氢氧化钠 溶液, BioUltra, for molecular biology, 10 M in H2O
Sigma-Aldrich
氢氧化钠 溶液, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-15, ascites fluid
Sigma-Aldrich
氢氧化钠, BioXtra, ≥98% (acidimetric), pellets (anhydrous)
Sigma-Aldrich
氢氧化钠, puriss., meets analytical specification of Ph. Eur., BP, NF, E524, 98-100.5%, pellets
Sigma-Aldrich
氢氧化钠, reagent grade, 97%, powder
Supelco
氢氧化钠 溶液, 49-51% in water, eluent for IC
Supelco
氢氧化钠溶液, 0.1 M NaOH in water (0.1N), Eluent concentrate for IC
Sigma-Aldrich
氢氧化钠 溶液, 5.0 M
Sigma-Aldrich
氢氧化钠, puriss. p.a., ACS reagent, reag. Ph. Eur., K ≤0.02%, ≥98%, pellets
Sigma-Aldrich
氢氧化钠, pellets, semiconductor grade, 99.99% trace metals basis
Sigma-Aldrich
亚硫酸氢钠 溶液, purum, ~40%
Sigma-Aldrich
氢氧化钠, puriss. p.a., ACS reagent, K ≤0.02%, ≥98.0% (T), pellets
Sigma-Aldrich
氢氧化钠 溶液, purum, ≥32%
Sigma-Aldrich
氢氧化钠, beads, 16-60 mesh, reagent grade, 97%
Sigma-Aldrich
氢氧化钠, BioUltra, for luminescence, ≥98.0% (T), pellets
Sigma-Aldrich
氢氧化钠, reagent grade, 97%, flakes
Sigma-Aldrich
氢氧化钠, ultra dry, powder or crystals, 99.99% trace metals basis
Supelco
链霉素 溶液, ~1 mg/mL in 1 mM EDTA, analytical standard
Sigma-Aldrich
氢氧化钠, anhydrous, free-flowing, Redi-Dri, reagent grade, ≥98%, pellets
Sigma-Aldrich
3-乙基-2,4-戊二酮,互变异构体的混合物, 98%
Sigma-Aldrich
氢氧化钠-16O 溶液, 20 wt. % in H216O, 99.9 atom % 16O